Gilead CEO Takes Aim at Medicare Pricing: 'Pill Penalty' Threatens Drug Innovation

기사 요약

Gilead stock rose after Q3 earnings beat Wall Street estimates and strong HIV drug demand prompted an increased 2026 sales forecast.